DPPOS AD/ADRD Health Economics Evaluation

DPPOS AD/ADRD 健康经济学评估

• 批准号: 10702144
• 负责人: Jose Alejandro Luchsinger
• 金额: $ 25万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702144
• 关键词: Alzheimer' s disease related dementia; Caregivers; Caring; Cost utility; Data; Economics; Effectiveness; Exercise; Health; Health Care Costs; Health Care Sector; Intervention; Life Style; Medical; Medical Care Costs; Medicine; Metformin; Outcome; Participant; Placebos; Productivity; Randomized; Resources; Time; base; cost; cost effectiveness; cost-effectiveness evaluation; economic evaluation; health economics; intervention cost; mortality; simulation

With this supplemental request, in DPPOS AD/ADRD during 2022-2027, we propose to extend our previous analyses to evaluate the longer-term cost-utility and cost-effectiveness of the three original DPP interventions by incorporating additional data on resource utilization, costs, health states/status, health utilities, and mortality. To support these economic analyses, we will continue to collect information on resource utilization and costs associated with the interventions and with medical care outside the study, and information on health outcomes, health utilities, and survival. Based on the resource utilization and cost data collected during DPP/DPPOS, we will summarize the total healthcare costs associated with each of the three original DPP randomized interventions. As recommended by the Second Panel on Cost-Effectiveness in Health and Medicine (3), healthcare costs will include costs in the formal healthcare sector (e.g., costs associated with implementing and maintaining the DPP/DPPOS interventions, and costs of medical care outside the study), those in the informal healthcare sector (e.g., costs of time spent by participants on exercising and costs of time spent by caregivers), and those in the non-healthcare sector (e.g., costs arising from lost productivity). We will estimate the mean per capita healthcare costs associated with each of the three original DPP randomized interventions over the time course of DPP/DPPOS, and calculate the incremental healthcare costs of the ILS and MET interventions relative to placebo and each other from a healthcare sector perspective and a societal perspective.

根据此补充请求，在2022-2027期间的DPPO AD/ADRD中，我们建议扩展我们的 以前的分析以评估三个原始的长期成本效用和成本效益 通过合并有关资源利用，成本，健康状况/地位的其他数据，DPP干预措施， 卫生公用事业和死亡率。为了支持这些经济分析，我们将继续收集 有关资源利用以及与干预措施以及医疗服务相关的成本的信息 在研究之外以及有关健康结果，健康公用事业和生存的​​信息。基于 DPP/DPPO期间收集的资源利用和成本数据，我们将总结总计 与三种原始DPP随机干预措施中的每一个相关的医疗保健费用。作为 第二小组对健康和医学的成本效益推荐（3），医疗保健费用 将包括正式医疗保健部门的成本（例如，与实施和 维持DPP/DPPO的干预措施和研究外的医疗费用） 非正式医疗保健部门（例如，参与者花费的时间和时间成本的时间 由照料者和非保健部门（例如，生产力损失产生的成本）。 我们将估计与三个原始DPP中的每一个相关的人均医疗保健费用 在DPP/DPPO的时间过程中的随机干预措施，并计算增量 ILS的医疗保健费用与安慰剂相对于安慰剂的干预措施以及彼此之间的干预措施 医疗保健部门的观点和社会观点。